How long will markets sustain high priced orphan drugs?

The orphan drug market was worth more than $50 billion in 2011 and turns out blockbusters at the same rate as the broader industry, according to a recent Thomson Reuters analysis. This is mostly due to the high-prices of therapies developed by the industry for rare disease patients. Even though the segment has just started to provide a great source …